Early Mortality as a Quality Indicator in Frontline and Salvage Acute Myeloid Leukemia

Article Hematology

Prediction of early (4-week) mortality in acute myeloid leukemia with intensive chemotherapy

Koji Sasaki et al.

Summary: The progress in intensive chemotherapy and supportive care measures has improved survival in newly diagnosed AML patients. Risk classification based on factors such as age, frailty, organ dysfunction, cytogenetic abnormality, and infection can guide treatment intensity to avoid early mortality and improve survival rates.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Article Hematology

Prediction of survival with intensive chemotherapy in acute myeloid leukemia

Koji Sasaki et al.

Summary: This study analyzed the survival of newly diagnosed AML patients treated with intensive chemotherapy and identified adverse prognostic variables that are independently associated with worse survival. A predictive model was developed to estimate the patients' survival outcome, which can be used to guide treatment decisions and compare outcomes of different therapies.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Article Hematology

Venetoclax combined with induction chemotherapy in patients with newly diagnosed acute myeloid leukaemia: a post-hoc, propensity score-matched, cohort study

Curtis A Lachowiez et al.

Lancet Haematology (2022)

添加到收藏夹

Editorial Material Oncology

Early Death After Chemotherapy as a Quality Indicator-Is It Time to Bench the Benchmark?

Catherine Dunn et al.

JAMA ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Acute myeloid leukemia: current progress and future directions

Hagop Kantarjian et al.

Summary: Advancements in understanding and therapy of AML have been rapid, with targeted therapies such as venetoclax and FLT3 inhibitors being approved for various indications. Expertise is crucial in managing the complexity of AML treatment, tailored to the specific subentities for optimal outcomes.

BLOOD CANCER JOURNAL (2021)

添加到收藏夹

Review Oncology

Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach

Hagop M. Kantarjian et al.

Summary: Research on acute myeloid leukemia (AML) has progressed rapidly, with the US FDA approving 10 drugs for various AML indications since 2017. Different subsets of AML require tailored treatment strategies, including young patients fit for chemotherapy and older patients not suitable for intensive treatment, with combination therapy showing promising results.

CANCER (2021)

添加到收藏夹

Review Oncology

Acute Myeloid Leukemia: Historical Perspective and Progress in Research and Therapy Over 5 Decades

Hagop M. Kantarjian et al.

Summary: With the approval of 9 agents for different AML indications by the FDA, the prognosis and management of AML are rapidly evolving. This review highlights important milestones in AML research and therapy, discusses prognostic assessment and treatment outcome prediction, details practical supportive care measures, and summarizes the current treatment landscape and areas of evolving research.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2021)

添加到收藏夹

Article Oncology

Venetoclax Combined With FLAG-IDA Induction and Consolidation in Newly Diagnosed and Relapsed or Refractory Acute Myeloid Leukemia

Courtney D. DiNardo et al.

Summary: The combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin with venetoclax showed to be an effective treatment regimen in both newly diagnosed and relapsed or refractory AML patients, resulting in deep remissions and high rates of successful transplantation.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Hematology